Desonide .5 mg/g Cream — NDC 62332-632-60 (Billing 62332-0632-60)
This is a package of Desonide .5 mg/g Cream from Alembic Pharmaceuticals Inc., marketed since Dec 2022 and currently FDA-listed; retail pharmacies pay about $0.1974 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 62332-632-60 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 62332 labeler · 632 product · 60 package
- Package marketed since
- Dec 8, 2022
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC)
- 0362332632152, 0362332632602
- Medicaid fills, this package
- 1,890 prescriptions in the last four reported quarters
- FDA record last changed
- Aug 6, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007620
- GCN: 31425
- HICL (First Databank): 003322
- AHFS class code: 84:06.08.00
- RxCUI (RxNorm): 349351
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Desonide is used to treat the redness, swelling, itching, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Desonide is in a class of medications called topical corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Read the full MedlinePlus article ↗- It calms inflammation and itching from skin conditions that respond to steroids. The gel is specifically for mild to moderate eczema (atopic dermatitis) in people 3 months and olde...
- Put a thin layer on the affected skin and rub it in gently. How many times a day depends on your product, so follow your label and prescriber. Don’t cover the area with tight wraps...
- Use it for the shortest time that works. The gel should not go past 4 weeks in a row. The cream and ointment should not go past two weeks unless your doctor says so. Stop once your...
- Mild burning, rash, itching, dryness or irritation where you apply it. Call your doctor if the skin gets worse, thins, looks infected, or if you notice signs of too much steroid in...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Desonide — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.197 | $11.84 / 60 g |
| Medicaid paysCMS SDUD · 12 mo | $0.4588 | $27.53 / 60 g |
| Medicare drug plans payPart D · Q2 2026 | $0.6421 | $38.53 / 60 g |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 62332-0632-15 62332-632-15 | 1 TUBE in 1 CARTON / 15 g in 1 TUBE | $0.3056 / g | $4.58 | 2022-12-08 | — | Active |
| 62332-0632-60 You're viewing this Main listing | 1 TUBE in 1 CARTON / 60 g in 1 TUBE | $0.1974 / g | $11.84 | 2022-12-08 | — | Active |
This pack has the lowest per-g cost of the 2 priced pack sizes ($0.1974 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 60% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Desonide .5 mg/g Cream?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Desonide .5 mg/gthis 62332-0632-60 | Alembic | 1 tube | $0.197 | AB | Availability likely | — |
| Desonide .5 mg/g 00472-0804-15 | Actavis | 1 tube | $0.266 | AB | Discontinued | +35% |
| Desonide .5 mg/g 00713-0661-15 | Cosette | 1 tube | $0.306 | AB | Availability likely | +55% |
| Desonide .5 mg/g 16714-0729-01 | NORTHSTAR | 1 tube | $0.306 | AB | Availability likely | +55% |
| Desonide .5 mg/g 51672-1280-01 | Sun | 1 tube | $0.306 | AB | Availability likely | +55% |
| Desonide .5 mg/g 72578-0086-01 | Viona | 1 tube | $0.306 | AB | Availability likely | +55% |
| Desonide .5 mg/g 45802-0423-35 | Padagis | 1 tube | $0.392 | AB | Availability likely | +99% |
| Desonide .5 mg/g 72603-0164-01 | NORTHSTAR | 1 tube | $0.392 | AB | Availability likely | +99% |
| Desonide .5 mg/g 51672-1281-01 | Sun | 1 tube | $0.392 | AB | Availability likely | +99% |
| Desonide .5 mg/g 62332-0485-15 | Alembic | 1 tube | $0.392 | AB | Availability likely | +99% |
| Desonide .5 mg/g 46708-0632-15 | Alembic | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 63187-0747-15 | Proficient | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 63629-2506-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 63629-2507-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| Tridesilon Cream .03 g/60g 69482-0600-60 | Encore | 1 tube | — | — | FDA listed | — |
| Desonide .5 mg/g 70771-1381-01 | Zydus | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 72162-2005-02 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 80425-0371-01 | Advanced | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 80425-0418-01 | Advanced | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 24470-0920-60 | Cintex | 1 tube | — | — | FDA listed | — |
| Desonide .5 mg/g 46708-0485-15 | Alembic | 1 tube | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Desonide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 34S289N54E
Aluminum sulfate is a salt compound used in medicines as an astringent and buffering agent. It helps regulate acidity and can be used in topical or oral formulations to reduce moisture and control pH levels.
-
UNII Y882YXF34X
Calcium acetate is a mineral salt made from calcium and acetic acid. In medicines, it acts as a binder to hold ingredients together and can help control the acidity level of the formulation.
-
UNII 2DMT128M1S
A waxy solid derived from plant or animal sources. It acts as an emulsifier to blend oil and water components, and also thickens the medicine to give it the right texture and consistency.
-
UNII 7FLD91C86K
Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 2NX48Z0A9G
Icodextrin is a glucose polymer derived from starch. It acts as a thickening agent and osmotic agent in medicines, helping to control texture and absorption in formulations like eye drops or injectable solutions.
-
UNII N6K5787QVP
Light mineral oil is a clear, odorless liquid derived from petroleum. In medicines, it acts as a lubricant and emollient to help the product spread smoothly and improve texture.
-
UNII 4T6H12BN9U
Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
-
UNII 368GB5141J
A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
-
UNII 7G1J5DA97F
White wax is a refined, bleached plant-based or mineral wax that serves as a coating and hardening agent in medicines. It helps control how fast the drug dissolves and improves the product's texture and appearance.
11 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 5, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Alembic Pharmaceuticals Inc. labeler code 62332
- Mupirocin 20 mg/g Cream NDC 62332-624-15
- Travoprost ophthalmic solution .04 mg/mL Solution/ Drops NDC 62332-625-02
- Glycopyrrolate .2 mg/mL Injection NDC 62332-627-25
- Glycopyrrolate .2 mg/mL Injection NDC 62332-628-25
- Glycopyrrolate .2 mg/mL Injection NDC 62332-629-10
- Metronidazole 10 mg/g Gel NDC 62332-630-45
- Arformoterol tartrate 15 ug/2mL Solution NDC 62332-633-30
- Dabigatran Etexilate 75 mg Capsule NDC 62332-634-06
- Dabigatran Etexilate 110 mg Capsule NDC 62332-635-06
- Dabigatran Etexilate 150 mg Capsule NDC 62332-636-06
- Doxepin Hydrochloride 10 mg Capsule NDC 62332-637-31
- Doxepin Hydrochloride 25 mg Capsule NDC 62332-638-31
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Desonide cream USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Desonide cream USP, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide cream USP, 0.05% should not be used with occlusive dressings.
⛔ Contraindications ▾
CONTRAINDICATIONS Desonide cream USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide cream USP, 0.05% was approximately 1%. These adverse reactions were pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, and burning. Laboratory abnormalities were found in 3% of the patients.
These were hyperglycemia (2%) and liver function abnormality (1%). The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.
🆘 Overdosage ▾
OVERDOSAGE Topically applied desonide cream USP, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins.
It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics - The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier.
Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Studies performed with desonide cream USP, 0.05% indicate that it is in the low range of potency as compared with other topical corticosteroids.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Desonide cream USP, 0.05% is white to off white cream available as follows: 15 g tube (NDC 62332-632-15) 60 g tube (NDC 62332-632-60)
📦 Storage and Handling ▾
STORAGE Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA Manufactured by: Alembic Pharmaceuticals Limited (Derma Division), Karakhadi, Vadodara 391450, India. Mfg. License No.: G/25/2216 Revised: 8/2025
📋 Description ▾
DESCRIPTION Desonide cream USP, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in desonide cream USP, 0.05% is C 24 H 32 O 6 .
It has the following structural formula: The molecular weight of desonide is 416.51. It is a white to almost white crystalline powder. The solubility of desonide in distilled water saturated with ether is 184 mg/L.
Each gram of desonide cream USP, 0.05% contains 0.5 mg of desonide, USP microdispersed in a base of aluminum sulfate, calcium acetate, cetostearyl alcohol, dextrin, edetate disodium, glycerin, light mineral oil, purified water, sodium lauryl sulfate, white wax, and white petrolatum. Desonide cream USP, 0.05% is preserved with methylparaben and buffered to pH 4.2 to 5.0. Image
⚠️ Precautions ▾
PRECAUTIONS General - Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression.
This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than two weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppressions. One of ten patients treated for one week under occlusion (30% of body surface) with desonide cream USP, 0.05% developed HPA axis suppression as determined by metapyrone testing.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids.
For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS - Pediatric Use ). If irritation develops, desonide cream USP, 0.05% should be discontinued and appropriate therapy instituted.
Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used.
If a favorable response does not occur promptly, use of desonide cream USP, 0.05% should be discontinued until the infection has been adequately controlled. Desonide cream USP, 0.05% should not be used in the presence of infection at the treatment site, hypersensitivity to corticosteroids, or pre-existing skin atrophy. Desonide cream USP, 0.05% should not be used in the eyes.
FOR EXTERNAL USE ONLY. Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only.
Avoid contact with the eyes. This medication should not be used for any disorder other than that for which it was prescribed. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.
Patients should report to their physician any signs of local adverse reactions. Laboratory Tests - The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test A.M. plasma cortisol test Urinary free cortisol test Carcinogenesis, Mutagenesis, Impairment of Fertility - Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of desonide cream USP, 0.05%. Pregnancy: Teratogenic Effects: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with desonide cream USP, 0.05%. It is also not known whether desonide cream USP, 0.05% can cause… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Rx Only NDC 62332-632-15 Desonide Cream, 0.05% 15 grams 15 g tube label 15 g carton 60 g tube label 60 g carton